Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You do not have to hope for bad numbers to load up.
Tax loss selling should see this go to 25 cents.
Gio
IMSC still has to beat out Smith`s and Morpho.
There radioactive equipment is still approved.
Personal relationships are more important in selling then the latest gee whiz factor.
We all better start praying.. a long slog ahead..
Gio
I will sell for a tax loss soon.
IMSC Stockholder Wins Spelling Bee-g-
Have a great weekend.
Gio
Ready to book sales?Baloney
I hope you are correct but until they do
all is speculation
we have been awaiting sales for how llong now?
Gio
Thank you
Gio
No one is waiting for a safety designation!
Can IMSC sell?
It certainly seems like they cannot.
When has Glenn ever stated they were
waiting for a safety designation?
More fluff
Gio
premonition12 could have bought for $0.12 cents
on 9/1/12
when he posted this:
premonition12 Saturday, 09/01/12 10:27:24 AM
Re: lakes post# 7007
Post # of 9930
Lakes, I think you are confused by the legal posturing that takes place in these type of cases. I think it's funny because finally someone is holding DECN accountable to their "forward looking statements"(wink wink). The company has lead shareholders to believe that the launch of Genstrips have been imminent since 2010-WITH BIG PUMPING PR'S, FORWARD LOOKING STATEMENTS IN FILINGS, GUIDANCE REPORTS, ETC. ETC. Lifescan is simply pointing to these statements and DECN has been backtracking every step of the way. (ie Genstrip FDA Approval-in court stated very real possibilty that Genstrip wlll never be approved, stated in filings they were stockpiling Genstrips for launch-in court backtracked to producing Genstrips for FDA shelf life testing-which is kind of funny considering they stated big huge 3rd Q2010 revenues coming. This is all just too funny, they are eating those words now. It would be foolish to think that Genstrips will be launched anytime soon. All jmho
Insignificant sales are to blame for this stock price
No rats , no fish, no significant sales
gio
PR`s are fluff, IMSC numbers please?
no state secrets being given away!
2 units? or some other insignificant number..
getting tired of holding
Gio
The terrorist seeing what a great value IMSC stock price
buy and
only attack morpho and smiths
that`s a movie.
lol
common sense the most uncommon sense of all
Gio
Really? The terrorist might think the 19 airports have Smith/Moephos antiquated sniffers and get lazy because he is familiar with it. IMSC is doing right by their customer. Common sense.
I have spent a lot of time in LA&SA.
It would not surprise me if they mounted
one on a truck and drove from airport to airport.
Those places are poor.
Vague way too vague.
Saying 19 or whatever would be a good start but this is another piece of fluff.
Major airports? City to city? International?
Private fields?
Gio
I have spent a lot of time in LA&SA.
It would not surprise me if they mounted
one on a truck and drove from airport to airport.
Vague way too vague.
Gio
As always Thank You Guys!! Leirum MrS CDNboy
swanlinbar Ksuave tpc7 sammy and all of the rest.
A spatial thanks to Alydyr for his contrarian view.
Gio
How Many QS-B220 for these 19 airports?
19? 38? 57? 76?
2?
IMSC please care about your shareholders.
Gio
IMSC Russian Star Sales Agent Missing The Action!
How many options they give this star?
link was to dissent
Sales are slow to say the least.
If IMSC cannot sell these systems which they seem incapable of,
hopefully Smiths or Morpho would buy them!
Terrorist attacks and deaths hit record high, report shows
By Daniel Burke, CNN Belief Blog co-editor
Washington (CNN) – As terrorism increasingly becomes a tactic of warfare, the number of attacks and fatalities soared to a record high in 2012, according to a new report obtained exclusively by CNN.
More than 8,500 terrorist attacks killed nearly 15,500 people last year as violence tore through Africa, Asia and the Middle East, according to the National Consortium for the Study of Terrorism and Responses to Terrorism.
That’s a 69% rise in attacks and an 89% jump in fatalities from 2011, said START, one of the world’s leading terrorism-trackers.
Six of the seven most deadly groups are affiliated with al Qaeda, according to START, and most of the violence was committed in Muslim-majority countries.
The previous record for attacks was set in 2011 with more than 5,000 incidents; for fatalities the previous high was 2007 with more than 12,800 deaths.
Much More @ link:
http://religion.blogs.cnn.com/2013/10/28/terrorist-attacks-and-deaths-hit-record-high-report-shows/
DECN Creating A Major Earthquake in the Glucose monitoring biz!
DECN Completes First Major Shipments of its Popular Genstrip Test Strip.
The Major Kicker is when The USPTO declares DECN the winner
and J&J chumps. Any Day Now!
DECN to ship $25 Million before Christmas! $50 Million?
What will the stock price be:O)
Better sell now dead money:O)
COLLAPSE
Drought Led to Collapse of Civilizations
DECN down one half of a penny
Collapse ? you decide!
Gio
DECN seems to have a Two Week Time Period
before Great News penetrates
and monkeys hit the buy button!
The knowledge is here for all to see yesterday,
oh well.
I could not believe when the news came out that
the preliminary USPTO decision was 5 to zero in DECN favor
and the stock stayed 15 to 20 pennies for two weeks.
Gio
Leirum Thank You! What A Deal! Wooo Hooo
Saw this and picked up a partial 4500 shares for .70
=============================
Decision Diagnostics Receives Signed Term Sheet Agreement For $12.5 Million Revolving Credit Facility Which Will Complete DEC...
10/29/2013 @ 9:15AM
Access Wire
Decision Diagnostics (DECN)
Quote :
0.71 0.0 (0.00%) @ 8:22AM
Decision Diagnostics Receives Signed Term Sheet Agreement For $12.5 Million Revolving Credit Facility Which Will Complete DEC...
- New 5-year credit facility amounts to total annual financing of $250+ million
- DECN reviewed competing offers, is now considering acquisitions pool proposals
- Current trade debt of approx. $2.8 million to be retired, enhancing balance sheet
- $12.5 million commercial line will NOT have an equity component
LOS ANGELES, CA - (ACCESSWIRE - October 29, 2013) - Decision Diagnostics Corp. (OTCBB:DECN) the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip™, the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that that the Company has received a Term Sheet Agreement for a $12.5 million revolving credit line from Alpha Credit Resources, LLC, a division of Platinum Credit Management LP of New York, NY. The new $12.5 million credit line will be totally equity free (no share dilution) and when matched with the company's current 1.8X sales turns per month (velocity), this credit facility will finance company sales of its GenStrip product line through $250+ million annually. The closing of the credit line and initial take-down is subject to DECN Board approval and the usual and customary documentation required for commercial credit and is expected early in November.
"Our credit line provides substantial resources for the Company to initiate our important, aggressive and revolutionary GenStrip business strategies," commented Keith Berman, DECN's Principal Officer, CFO and the GenStrip Program Director. "We want to make it clear to our shareholders, and the investing public, that our commercial lender Platinum Credit Management does not view Decision Diagnostics as a small business and is backing up their beliefs with $12.5 million. Thus, DECN never had to turn to stock market arbitrages such as equity lines of credit, equity participation agreements or any other type of toxic financing."
DECN is a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill and a premier developer of revolutionary cell phone centric e-health products and technologies. DECN's FDA cleared Shasta GenStrip™ product was first introduced to the market in late 2012 as a lower cost (50%) alternative for user/owners of Johnson and Johnson LifeScan OneTouch® Ultra®, Ultra2® and Ultra Mini® glucose meters.
Mr. Berman continued, "With the significant revenue streams GenStrip will produce, when coupled with our renewed access to $12.5 million of growth capital, we are now well positioned to complete the launch of GenStrip and embark on our mission. With a large and timely credit line coming into place, the company is now considering an offer for a $2.5 million M&A pool."
The company also reminds shareholders and all interested parties that it continues to air its new commercial video titled "GenStrip: A Patchwork of Life." The company plans on releasing a media schedule in the coming days. In the meantime, the extremely popular video is available for viewing at: shastagenstrip.com or youtu.be
Forward Looking Statements:
This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.
For further information about Shasta GenStrip, please visit the company's Web Sites: decisiondiagnostics.com or shastagenstrip.com
GenStrip™ test strips are a product of Shasta Technologies, LLC and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan®, Inc. a Johnson & Johnson® Company, manufacturers and distributors of the OneTouch® Ultra® Family of Meters and OneTouch® Ultra® test strips.
Contact:
Decision Diagnostics Corp.
Keith Berman
(805) 446-2973
info@decisiondiagnostics.com
Witness recounts bus ride with Russian suicide bomber
What is our Russian rep doing?
Gio
MOSCOW — THE NEW YORK TIMES NEWS SERVICE
Last updated Tuesday, Oct. 22 2013, 9:16 AM EDT
It was impossible not to notice her, one witness said. The young Muslim woman, her head covered by a light green scarf, boarded the No. 29 bus in Volgograd and took a seat near the back. She rode for two stops. Then she blew herself up.
In a horrific flash of fire and noise, the woman, identified by the authorities as Naida Asiyalova, detonated a bomb belt made of blocks of TNT and two grenades and packed with metal screws and chips, killing six passengers in addition to herself, and wounding at least 33 others.
Investigators immediately labeled the bombing a terrorist attack and said it was the latest case in which violence in the turbulent North Caucasus spilled into the Russian heartland.
Officials said that Asiyalova’s husband, Dmitri Sokolov, is a demolitions and explosives expert for a rebel group based in Makhachkala, the capital of Dagestan, where Russian security forces have been engaged in a fierce effort to suppress Muslim separatists.
While Muslim rebels in the Caucasus have made a deadly practice in recent years of recruiting “black widows” – the wives of slain fighters – to serve as suicide bombers, investigators said Asiyalova’s case had an unusual twist: She apparently recruited Sokolov after they met as students in Moscow. He converted to Islam and, according to local news reports, dropped out of the sight of family members in June 2012, apparently moving with Asiyalova to Dagestan to join the local jihad.
Asiyalova was four days shy of her 31st birthday, according to a passport found near the scene that shows her in a photograph wearing a black head scarf, and she was apparently suffering from a grave illness. A Web page on a Russian social media site pleaded for donations to help her obtain medical treatment for a painful disease that had weakened her bones and left her dependent on painkillers and tranquilizers.
The witness who noticed the green scarf, Irina Kushnir, said, “I immediately paid attention to her,” according to the newspaper Komsomolskaya Pravda. Kushnir said that she had left work early to go to a doctor’s appointment and that the woman in the scarf had given no hint of the grisly attack she was about to carry out.
Vladimir Markin, a spokesman for the federal Investigative Committee, identified Asiyalova as the suicide bomber in a statement Monday evening and said officials were collecting forensic evidence from the scene and reviewing images from numerous surveillance cameras.
DECN Read This For A very Pleasent Rest Of Your Life!
http://www.uiowa.edu/~ibl/documents/SSRN-id1920215.pdf
Gio
The Third Ace! Got this USPTO ruling. Looks to me DECN should have something to smile.
--------------
Leirum
Friday, 08/16/13 12:04:04 PM
Re: None
Post # of 9634
Got this USPTO ruling. Looks to me DECN should have something to smile.
CONCLUSION
For the foregoing reasons, we determine that Pharmatech has demonstrated
that there is a reasonable likelihood of its proving unpatentability of claims 1-3 of
the '105 patent by a preponderance of the evidence.
IV. ORDER
For the reasons given, it is
ORDERED that the Petition is granted as to claims 1-3 with respect to the
following grounds:
1. Unpatentability of claims 1-3 under 35 U.S.C. ? 103(a) for
obviousness over Nankai and Schulman; and
2. Unpatentability of claims 1-3 under 35 U.S.C. ? 103(a) for
obviousness over Winarta and Schulman;
FURTHER ORDERED that pursuant to 35 U.S.C. ? 314(a), inter partes
review of the '105 patent is hereby instituted commencing on the entry date of this
Order, and pursuant to 35 U.S.C. ? 314(c) and 37 C.F.R. ? 42.4, notice is hereby
given of the institution of a trial;
Are DSS litigation lawyers competent?
Recognized Healthcare and Financial Publications Acknowledge Decision Diagnostics’ GenStrip Market Potential
Los Angeles, CA - (October 22, 2013) Decision Diagnostics Corp. (DECN) the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip[TM], the unique diabetes monitoring Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (JNJ) LifeScan Ultra family of glucose testing meters has been the focus of favorable articles and papers published recently. Today BioMedReports released an article on the front page of their website titled “DECN Set to Climb as GenStrip Enters Blood Glucose Monitoring Market With New Large Shipments.” The article summarizes DECN’s history and current business. The full article can be read here:
http://www.biomedreports.com/20131022158602/decn-set-to-climb-as-genstrip-enters-blood-glucose-monitoring-market-with-first-shipments.html
Decision Diagnostics has also been featured in articles in Forbes, Qmed and Seeking Alpha in the past few months. All of these articles are available online on their respective websites.
Keith Berman, Principal Executive Officer of Decision Diagnostics, commented, “Decision Diagnostics has begun shipping large box quantities of Shasta GenStrip glucose monitoring test strips and we are pleased that the disruptive market potential of the product line is being recognized and written upon by financial and healthcare publication.”
About BioMedReports
BioMedReports.com is the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions. Visit http://www.biomedreports.com/.
About Decision Diagnostics:
DECN is a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill and a premier developer of revolutionary cell phone centric e-health products and technologies. DECN's FDA cleared Shasta GenStrip™ product was first introduced to the market in late 2012 as a lower cost (50%) alternative for user/owners of Johnson and Johnson LifeScan OneTouch® Ultra®, Ultra2® and Ultra Mini® glucose meters.
Forward-Looking Statements:
This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates," "will" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.
For further information about Shasta Genstrip, please visit the company's web sites: http://www.decisiondiagnostics.com/ or http://www.shastagenstrip.com/.
GenStrip[TM] test strips are a product of Shasta Technologies, LLC and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan[R], Inc. a Johnson & Johnson[R] Company, manufacturers and distributors of the OneTouch[R] Ultra[R] Family of Meters and OneTouch[R] Ultra[R] test strips.
Contact:
Decision Diagnostics Corp.
Keith Berman(805) 446-2973
info@decisiondiagnostics.com
Red Sox and bombing-scarred Boston rise together
without IMSC
http://www.bostonglobe.com/metro/2013/10/22/red-sox-redemptive-season-aided-city-recovery-after-boston-marathon-bombings/oO7LvQ8fNgmiCPk5CBNFYL/story.html
Gio
pulpman please step up and buy
There will be bomb-sniffing dogs @ World Series
and metal detectors.
ST. Louis
St. Louis to beef up security for World Series
STLtoday.com ?- 18 hours ago
There will be bomb-sniffing dogs. And officers will have video ... Dotson said the approach to the World Series has three parts. Security is on the ...
http://www.stltoday.com/news/local/metro/st-louis-to-beef-up-security-for-world-series/article_bbd4fad6-b141-514c-b6a8-d8bd3f4e90f0.html
Decision Diagnostic Blood Glucose Test Strip Technology Enters Market with Genstrip
Small Decision Diagnostics Making Inroads with New FDA Approved Blood Glucose Test Strip.
Los Angeles, CA (PRWEB) October 22, 2013
Los Angeles, Ca. October 17, 2013 Decision Diagnostics Corp., the exclusive worldwide sales, service and regulatory processes agent for the GenStrip™, the Green Test Strip, specifically designed to work with the Johnson & Johnson's LifeScan family of glucose testing meters, is poised to enter one of J&J’s strongest product’s market share in the at home glucose test strip market.
In March of this year, Forbes’ article “…Lucrative Glucose Monitoring Business From Tiny Diagnostics Outfit”, detailed the business of glucose monitoring growing at a rate of 25% annually, and experts estimate that by 2017, the market will exceed $30 billion worldwide.
Keith Berman, the CEO of Decision Diagnostics said, “we are very excited by the initial response to GenStrip™, we had some challenges implementing our packaging and marketing plans” and Berman continued, “but being a small company we have the talent and resources to make effective changes quickly and maintain our momentum.”
And GenStrip momentum could lead to a substantial market share and profits. Diabetic testing is estimated to generate about 23 billion in annual revenue with experts estimating the market will grow to 30 billion by 2017. This includes J&J’s LifeScan Ultra meters and glucose test strips and among the diabetics who test their own glucose levels at home on a daily bases.
Berman stated, “Our product performance is strong and the statistics bear that out; and with FDA approval and our pricing model; we felt it was important not only to our shareholders, but for the at home diabetic test strip community as well to get GenStrip™ to market in a timely manner.”
And an article that appeared in MarketWired on September 3rd titled supports Berman’s strategy, “Decision Diagnostic’s GenStrip Could Change the Blood Glucose Market” states that GenStrip™ will be well received due to new payment changes for test strips caused by Medicare’s mandated competitive bidding policies that started in July 2013.
Berman discussed GenStrip™ as a viable solution to the mandate, “Our new Mail Order/Competitive Bidding version will offer the market an alternative to the ‘direct to patient’ fulfillment model with a high quality diabetic test strip that is profitable without forcing diabetics to endure rising cost of co-payments.
Decision Diagnostic is preparing to roll out the next generation of GenStrip™, which the company believes will fill a niche in the diabetes testing market that is still virtually unmet, says Berman. “This is a high stakes game, but the bottom line for us is providing a cost-effective solution for diabetics so they can maintain their quality of life”.
GenStrip™
Thanks Lakes
Gio
If one police agency would use them maybe it would crack the ice.
That is why you should care.
Gio
You bettor, get to know Glenn better.
Gio
IMSC has sold 150`s to the MASS State Police.
IMSC offered the city of Boston use of handhelds.
There is a standing offer.
Yes I knew the answer.
You should too.
Gio
I care! The publicity of protecting the World Series!
jeez louise
Gio
IMSC offered and the city declined
Ask Glenn.
Gio
You could be right but a broken down chart does not auger well;O)
GLTA
Gio
"Raising capital at these levels is not something we want to do"!
Really? Where was the forethought on raising money when their stock was @$4 or $3?
I believe the money has DSS over a barrel and they will be forced to do a very, very lousy financing.
Al;ong with tax selling this is going to be a tough Nov and Dec for Dss.
"In addition to registering the stock underlying these warrants, DSS registered up to fifteen million shares of common stock which could be used to raise capital through the future sale of equity. Once the shelf is made effective, DSS may seek strategically to sell its common stock by pulling shares off the shelf in one or more offerings, in amounts, and at prices, to be determined. DSS has no immediate plans to do so based on current market prices.
Peter Hardigan, COO of DSS stated, "As a public company, we intend over the long term to use our balance sheet to fund all our acquisitions, however at this point in time, it makes sense to share risk with private investors focused on the monetization part of our business as we diversify our IP investments. Raising capital at these levels is not something we want to do"
All fake sugars have 95% of the Glucose content of real sugar!
Gemstrips should be attached to every candy bar-g-
Sugar substitues are not an answer to fight disease.
Fruit and tomatoes arer all sugar. I had strawberries sweeter then candy this summer. A friend with lupus had an episode caused by bell peppers and tomatoes, too much sugar!
We live in a crazy world.
Sugar was not widely available thru history until the 1600`s.
Then it was so expensive and rare that Jack The Ripper got his women by offering them a grape in the 1800`s.
Please read
Dr. William Davis
Wheat Belly
for a health plan for you and your family.
Only thing I would add to Dr. Davis is take
D3 until your 1.25OH is at least 100.
I am going for 200 and I take 50,000 iu D3 daily.
D3 has cured arthritis in my hips.
My wife has had her rheumatoid arthritis knuckles melt away
back to how her hands use to look.
She has regained the ability to open bottles and her grip has come back.
"First, the authors report that vitamin D had remarkable treatment effects on all kinds of arthritis, especially rheumatoid arthritis. They report on 67 arthritic patients so treated, with 75% of the patients responding most dramatically.
The dose used? Drs. Dreyer and Reed started all patients on 200,000 IU per day! They started some patients on 200,000 IU/day of D2 and others on 200,000 IU/day of D3, noticing no difference in efficacy. They used vitamin D preparations made by Mead Johnson, Glaxo, and Abbott."
http://www.vitamindcouncil.org/newsletter/newsletter-gary-null-and-vitamin-d-toxicity/
GLTA
Gio